Bosulif
$1,024.00
Bosulif is indicated for the treatment of adult patients with leukemia
Bosulif is indicated for the treatment of adult patients with:• newly diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).• chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Brand Manufacturer: Order – August 26, 2024 @ 11:55 PM
Side Effects: As with any medicine, use of Bosulif®may cause side effects in some users. Do not be alarmed when reading the list of side effects. You may not suffer from any of them.Contact the doctor immediately if you experience any of the following seriousside effects:•Blood disorders. Contact the doctor immediately if you have any of the followingsymptoms: bleeding, easy bruising or fever,you might have blood or lymphatic system disorder.•Liver disorders. Contact the doctor immediatelyif you have any of the followingsymptoms: itching, yellow eyes or skin, dark urine and pain or discomfort in the right upper stomach area or fever.•Stomach/intestinal disorders.Tell the doctor if you develop heartburn, stomach pain, diarrhea, constipation, nausea and vomiting.•Heart problems. Tell the doctor if you have a heart disorder, such as heart rhythm disorders, or an abnormal electrical signal called prolongation of the QTinterval, or if you lose consciousness (faint) while taking Bosulif®.•HepatitisB reactivation. Recurrence (reactivation) of hepatitisB (a viral liver infection)if you have had hepatitisB in the past.•Serious skin reactions.Tell the doctor immediatelyif you have any of the followingsymptoms: painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membranes (e.g. mouth and lips).
Indication: Bosulif®is intended for the treatment of adult patients with:•newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+CML).•chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Reviews
Write a review
The product has no reviews
Leave your review
